These results suggest that MnSOD expression level in tumor tissue is a candidate marker for the prognosis of glioblastoma patients.
The prognosis of glioblastoma patients remains poor despite recent therapeutic advances involving multidisciplinary strategies. Nevertheless, 1-17% of glioblastoma patients survive for more than 3 years (long-term survival glioblastoma, LTSGBL, patients) [1] . Characterization of this subgroup of patients may help to elucidate the biological behavior of glioblastomas. Although molecular profiling has been used to identify biomarkers of LTSGBL [2] [3] [4] , protein expression profiles have not been reported for LTSGBL tissue. In the present study, a proteomic approach involving two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization timeof-flight mass spectrometry (MALDI-TOF MS) was used to identify markers for LTSGBL by comparing the protein expression profile of LTSGBL tissue with that of short-term survival glioblastoma (STSGBL) tissue. Western blot (WB) analysis, the reverse-transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical (IHC) staining were used to validate differentially expressed proteins.
Materials and Methods
Clinical data of the 8 glioblastoma patients whose tumor tissues were used in this study are summarized in GTR = Gross total removal; STR = subtotal removal; RTx = radiation therapy; CTx = chemotherapy; GKS = gamma knife surgery. were performed as previously reported [5] . 
Results
The cross analysis of 4 sets of 2-DE images (2 LTSGBLs and 2 STSGBLs) revealed 8 candidate spots ( fig. 1 ). These spots were consistently present in all samples but their expression levels differed between samples identified using MALDI-TOF MS and database searching ( table 2 ) . Of these molecules, MnSOD was the only one that was consistently expressed in 2-DE, WB, IHC, and RT-PCR analyses ( fig. 2 ) . MnSOD was overexpressed in STSGBL samples. To confirm this result, WB analysis and RT-PCR using an MnSOD probe were performed using a series of samples from patients other than those used in the first analysis (2 LTSGBL and 2 STSGBL patients). The results of the second series were the same as those of the first (data not shown).
Discussion
Although molecular profiling of this rare subset of LTSGBLs and its characterization is important for effective improvement of treatment of this devastating disease, few studies have been conducted [1] . In the present study, we used a proteomic molecular-profiling approach to identify markers associated with LTSGBLs and observed that a lack of overexpression of MnSOD may predict long-term survival of glioblastoma patients. MnSOD is an important antioxidant enzyme that protects cells from oxidative stress by catalyzing the conversion of the superoxide radical (O 2 -) to hydrogen peroxide and molecular oxygen in the mitochondria [6] . The results of previous in vitro studies using various cancer cell lines are conflicting, indicating that MnSOD is either a tumor suppressor or a tumor enhancer [7, 8] . However, the role of MnSOD as a tumor enhancer or a poor prognostic fac- Color version available online tor of human cancer is evident from the results of clinical studies [9] . Several mechanisms may underlie the prognostic value of MnSOD. Firstly, a high MnSOD level in tumor tissue is associated with resistance to radiation therapy or chemotherapy [10] . Secondly, overexpression of MnSOD is associated with inactivation of p53, which causes tumor cells to escape cell death, to survive and to proliferate under stress conditions [11] . In summary, molecular profiling of tissue samples of LTSGBL using a proteomic technique showed that a lack of overexpression of MnSOD protein and mRNA is consistent in LTSGBLs. And it was concluded that the level of MnSOD expression is a candidate prognostic factor in glioblastoma patients. Further studies with additional cases are warranted to confirm the predictive value of MnSOD expression and its role in the pathogenesis of malignant gliomas.
